Navigation Links
ViroPharma Incorporated Reports Fourth Quarter and Full Year 2011 Financial Results
Date:2/28/2012

result, our ability to respond to the comments raised by the FDA regarding our manufacturing process may exceed the timeframe we currently anticipate and we cannot assure that we will be capable of generating the data requested by the FDA in the timeframe we anticipate. In addition, the FDA may request additional data, require additional conformance batches, delay any decision past the time frames anticipated by us, or deny the approval of the industrial scale manufacturing process. If the manufacturing capacity expansion projects at Sanquin are delayed, or do not result in the capacity we anticipate, if Sanquin cannot obtain necessary regulatory approvals for the contemplated facility expansions in the time frames we anticipate or if we are not able to manufacture the anticipated volume of product at the existing scale, we may not be able to satisfy patient demand. Our inability to obtain adequate product supplies to satisfy our patient demand may create opportunities for our competitors and we will suffer a loss of potential future revenues. These factors, and other factors, including, but not limited to those described in ViroPharma's annual report on Form 10-K for the year ended December 31, 2011, could cause future results to differ materially from the expectations expressed in this press release. The forward-looking statements contained in this press release may become outdated over time. ViroPharma does not assume any responsibility for updating any forward-looking statements. VIROPHARMA INCORPORATEDSelected Financial InformationConsolidated Statements of Operations:Three months endedTwelve months ended(in thousands, except per share data)

December 31,December 31,2011201020112010(unaudited)Revenue:Net product sales

$ 145,575$ 121,623$ 544,374$ 439,012Costs and Expenses:Cost of sales (excluding amortization of product rights)

19,68317,93479,97661,288Research and development

12,70710,46066,47739,613Selling, general and administrativ
'/>"/>

SOURCE ViroPharma Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. ViroPharma to Present at Three September Healthcare Conferences
2. ViroPharma to Present at Three October Healthcare Conferences
3. ViroPharma to Release 2008 Third Quarter Financial Results on October 29, 2008
4. ViroPharma Enhances Leadership to Support Global Growth and Expanding Business
5. ViroPharma to Present at Three November Healthcare Conferences
6. ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results
7. ViroPharma Improves Financial Position Through Repurchase of $45 Million Principal Amount of Senior Convertible Notes
8. ViroPharma to Release 2009 First Quarter Financial Results on April 29, 2009
9. ViroPharma Incorporated Reports First Quarter 2009 Financial Results
10. ViroPharma Incorporated Honored by the National Organization for Rare Disorders
11. ViroPharma to Present at Two June Healthcare Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... Aug. 27, 2015 The National Necrotizing ... eyes—and life—were saved by doctors at Vanderbilt University Hospital ... NNFF, NovaBay Pharmaceuticals and Dr. John Crew , ... at Seton Medical Center in Daly City, ... a breakthrough approach, pioneered by Dr. Crew, that had ...
(Date:8/27/2015)... Inc. (TSXV: BRM) ("Biorem" or "the Company") today announced its results ... complete second quarter financial statements and MD&A have been filed on ... per shareThree-months ended , Six -months endedJune 30 , June 30 ... 2014 Revenue , 4,709 , 2,459 ... 1,656 , 56 , 3,188 , ...
(Date:8/27/2015)... YORK , August 27, 2015 ... enhancing image processing functions in the human vision system, announced ... point guard Chris Paul to develop ... players who want to improve their real-life on-court performance. ... the court, whether it is shooting a ball or blocking ...
(Date:8/27/2015)... ... 2015 , ... METTLER TOLEDO's web-based EasyFinder™ tool ... to a manageable shortlist of bench and floor scales and terminals. Specifying a ... with the customer’s industry and application. , Side-by-side product comparisons and an ...
Breaking Biology Technology:Patient's Life and Eyes Saved from Gruesome Flesh-Eating Infection Consuming Her Face 2Patient's Life and Eyes Saved from Gruesome Flesh-Eating Infection Consuming Her Face 3BIOREM Reports $718,000 Net Earnings for the Second Quarter 2BIOREM Reports $718,000 Net Earnings for the Second Quarter 3Eight-Time All-Star Chris Paul and GlassesOff Partner to Develop Innovative Mobile App Designed to Improve On-Court Performance 2Eight-Time All-Star Chris Paul and GlassesOff Partner to Develop Innovative Mobile App Designed to Improve On-Court Performance 3METTLER TOLEDO Updates Online Scale Selection Tool 2
... ... about fast, new treatment program for FIV and FELV , ... New York, N.Y. (PRWEB) November 4, 2009 -- IMULAN BioTherapeutics, LLC ... fast way to get LTCI for feline immunodeficiency virus (FIV) and feline leukemia virus (FeLV). ...
... ... To Target Tissues Affected by Osteoarthritis. Physics and Biology are Natural Partners in the ... ... medical device, the MyPhield Arthritis Therapy Cushion that naturally relieves osteoarthritis without causing unwanted ...
... Nov. 3 VIVUS, Inc. (Nasdaq: VVUS ... of novel therapeutic products, today reported its highlights and financial ... , Third Quarter Highlights , In ... two final, phase 3 pivotal 56-week studies, EQUIP (OB-302) and ...
Cached Biology Technology:New Program Developed in the Fight Against Feline Aids 2New Technology Now Available In Canada For Osteoarthritis 2VIVUS Reports Third Quarter 2009 Highlights and Financial Results 2VIVUS Reports Third Quarter 2009 Highlights and Financial Results 3VIVUS Reports Third Quarter 2009 Highlights and Financial Results 4VIVUS Reports Third Quarter 2009 Highlights and Financial Results 5VIVUS Reports Third Quarter 2009 Highlights and Financial Results 6VIVUS Reports Third Quarter 2009 Highlights and Financial Results 7VIVUS Reports Third Quarter 2009 Highlights and Financial Results 8
(Date:8/19/2015)... , Aug. 19, 2015  VOXX International Corporation ... has entered into a Definitive Agreement to purchase ... iris authentication market leader EyeLock through an acquiring ... have a controlling interest in the acquiring entity. ... completion of due diligence.  Expanding on its existing ...
(Date:8/12/2015)... 12, 2015   MedNet Solutions , an innovative ... of clinical research, is proud to announce that ... SaaS-based eClinical technology platform, has led the way to ... quarters of 2015.   Q2 2015 and Q1 2015 ... by contract value sold in the company,s 15 year ...
(Date:8/11/2015)... Today, ZUK announced its Android smartphone Z1, featuring FPC,s touch ... 2015 that relate to sales of FPC1155 for this smartphone model ... for 2015. Jörgen Lantto, CEO of FPC, comments: " ... manufacturer in China and we are proud ... for Z1 , its first ...
Breaking Biology News(10 mins):VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 2VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 3VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 4VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 5MedNet Solutions Experiences Explosive Corporate Growth 2FPC's Touch Fingerprint Sensor FPC1155 in ZUK's Smartphone Z1 2
... Rochelle, NY, September 1, 2010Biopharmaceutical firms and ... steps toward creating greener working environments and ... Engineering & Biotechnology News (GEN). This ... series of presentations and panel discussions that ...
... Biophysicists in Bochum have discovered a diode for protons: ... flow of electric current, the "proton diode" ensures that ... one direction. Water molecules play an important role here ... by Prof. Dr. Klaus Gerwert (Chair of Biophysics at ...
... reintroduction of wolves to Yellowstone National Park in 1995 is helping ... elk hungry for winter food had a different idea. They did ... of fear." According to a study set ... of the Ecological Society of America, the fear of wolf predation ...
Cached Biology News:GEN reports on the greening of the life sciences 2Bochum's researchers discover proton diode 2Are wolves saving Yellowstone's aspen trees from elk? 2Are wolves saving Yellowstone's aspen trees from elk? 3
... This product is expected to react ... species but has not been specifically ... precipitin line against partially purified rabbit ... react with all forms of Pyruvate ...
Rabbit polyclonal to Somatostatin 28 ( Abpromise for all tested applications). entrezGeneID: 6750 SwissProtID: P61278...
... Convenient platform for tube handling and reagent ... 0.2ml V-bottom tubes - 96 x ... - Thermo-Fast® 96 Non-Skirted Plate ... - 48 x 0.5ml Thermo-Tubes Multiple workstations can be ...
... Pro upgrade for Shimadzu Phoretix 2D, Expression ... statistical tools for comparative gel analysis studies ... Data base add on component ... version 9i release 2 client software). ...
Biology Products: